by | May 17, 2022 | Uncategorized
Source: Cure Today articles The combination of Sarclisa, Kyprolis and dexamethasone improved progression-free survival in patients with pretreated, relapsed myeloma, and has potential to become a new standard of care, an expert said. Read More
by | May 10, 2022 | Uncategorized
Source: Healio News Black patients appeared consistently underrepresented in pivotal clinical trials that led to FDA approval of several chimeric antigen receptor T-cell therapies, according to findings published in JAMA Network Open.Researchers from University of...
by | May 5, 2022 | Uncategorized
Source: Healio News The FDA recently granted breakthrough therapy designation of a HER2-directed antibody drug conjugate for the treatment of certain adults with unresectable or metastatic HER2-low breast cancer.The designation applies to patients who previously...
by | Apr 28, 2022 | Uncategorized
Source: Healio News The FDA granted orphan drug designation to ALLO-605, a chimeric antigen receptor T-cell therapy for adults with relapsed or refractory multiple myeloma.ALLO-605 (Allogene Therapeutics) is an allogeneic, gene-edited CAR T-cell therapy that targets...
by | Apr 26, 2022 | Uncategorized
Source: Healio News SALT LAKE CITY — Academic center outreach to community practices considerably increased stem cell transplant referrals for patients with multiple myeloma, according to study results.The approach resulted in a significant increase in the number of...
by | Apr 24, 2022 | Uncategorized
Source: Healio News Ciltacabtagene autoleucel induced a 95% overall response rate among patients with multiple myeloma who had early relapse after front-line therapy, according to results of a cohort analysis from the CARTITUDE-2 trial.Data from the study — presented...
